Published in J Infect Dis on July 20, 2004
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 2.74
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A (2013) 2.69
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94
Heterologous prime-boost vaccination. Curr Opin Immunol (2009) 1.84
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol (2012) 1.75
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. PLoS Comput Biol (2015) 1.70
Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol (2010) 1.51
Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV. Immunol Rev (2011) 1.44
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One (2010) 1.41
Immune correlates of vaccine protection against HIV-1 acquisition. Sci Transl Med (2015) 1.30
HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J Virol (2014) 1.29
A global approach to HIV-1 vaccine development. Immunol Rev (2013) 1.14
Is developing an HIV-1 vaccine possible? Curr Opin HIV AIDS (2010) 1.11
Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. Curr HIV Res (2013) 1.09
Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med (2012) 1.05
Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system. PLoS One (2013) 1.04
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. J Virol (2014) 1.03
The evolution of poxvirus vaccines. Viruses (2015) 1.02
Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother (2012) 1.00
A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responses. PLoS One (2011) 1.00
T-cell-inducing vaccines - what's the future. Immunology (2012) 0.95
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLoS One (2011) 0.93
Lessons drawn from recent HIV vaccine efficacy trials. J Acquir Immune Defic Syndr (2010) 0.92
Advances in FIV vaccine technology. Vet Immunol Immunopathol (2008) 0.91
Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa. J Acquir Immune Defic Syndr (2013) 0.89
Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials. PLoS One (2012) 0.88
Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection. J Infect Dis (2010) 0.87
Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials. Viruses (2010) 0.86
HIV-1 Vaccine Trials: Evolving Concepts and Designs. Open AIDS J (2012) 0.84
Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques. PLoS One (2013) 0.83
An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. Hum Vaccin (2010) 0.82
HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development. Curr HIV Res (2013) 0.80
Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection. AIDS Res Hum Retroviruses (2014) 0.79
Approaches to preventative and therapeutic HIV vaccines. Curr Opin Virol (2016) 0.79
Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E. PLoS One (2015) 0.79
HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1. J Biol Chem (2014) 0.78
Lessons from the failure of the adenovector HIV vaccine. F1000 Biol Rep (2009) 0.77
IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens. AIDS Res Hum Retroviruses (2015) 0.76
Recent update in HIV vaccine development. Clin Exp Vaccine Res (2016) 0.76
Hope for HIV control in southern Africa: The continued quest for a vaccine. PLoS Med (2017) 0.75
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. J Infect Dis (2016) 0.75
Microdevices for examining immunological responses of single cells to HIV. Biosci Rep (2014) 0.75
New prospects for a preventive HIV-1 vaccine. J Virus Erad (2015) 0.75
Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains. Vaccine (2016) 0.75
HIV Diagnosis and Treatment through Advanced Technologies. Front Public Health (2017) 0.75
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis (2002) 7.81
Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med (2006) 5.54
Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation (2007) 4.97
The staufen/pumilio pathway is involved in Drosophila long-term memory. Curr Biol (2003) 4.82
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med (2005) 4.65
Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis (2008) 4.48
Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One (2012) 3.69
A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med (2013) 3.44
Laboratory systems and services are critical in global health: time to end the neglect? Am J Clin Pathol (2010) 3.16
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 2.74
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A (2013) 2.69
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis (2012) 2.68
Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology (2010) 2.61
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47
Rhodococcus equi: an emerging pathogen. Clin Infect Dis (2002) 2.45
The X chromosome is organized into a gene-rich outer rim and an internal core containing silenced nongenic sequences. Proc Natl Acad Sci U S A (2006) 2.44
Laboratory challenges in the scaling up of HIV, TB, and malaria programs: The interaction of health and laboratory systems, clinical research, and service delivery. Am J Clin Pathol (2009) 2.40
Stage-dependent production and release of histidine-rich protein 2 by Plasmodium falciparum. Trans R Soc Trop Med Hyg (2005) 2.38
Clustering of multiple specific genes and gene-rich R-bands around SC-35 domains: evidence for local euchromatic neighborhoods. J Cell Biol (2003) 2.38
Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis (2012) 2.37
Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med (2014) 2.27
Laboratory reference values for healthy adults from southern Tanzania. Trop Med Int Health (2008) 2.26
Comparative evaluation of selected diagnostic assays for the detection of IgG and IgM antibody to Orientia tsutsugamushi in Thailand. Am J Trop Med Hyg (2002) 2.18
International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One (2009) 2.03
Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine (2005) 1.96
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One (2013) 1.94
Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med (2002) 1.93
Critical role of developing national strategic plans as a guide to strengthen laboratory health systems in resource-poor settings. Am J Clin Pathol (2009) 1.88
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med (2014) 1.87
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol (2012) 1.75
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr (2007) 1.73
Circulating proviral HIV DNA and HIV-associated dementia. AIDS (2005) 1.68
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One (2013) 1.65
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. J Infect Dis (2012) 1.65
A new circulating recombinant form, CRF15_01B, reinforces the linkage between IDU and heterosexual epidemics in Thailand. AIDS Res Hum Retroviruses (2003) 1.64
International importance of robust breast device registries. Plast Reconstr Surg (2015) 1.61
Pythium insidiosum pleuropericarditis complicating pneumonia in a child with leukemia. Clin Infect Dis (2002) 1.60
A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis (2002) 1.56
Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis (2006) 1.54
Molecular Epidemiology of HIV Type 1 in Ecuador, Peru, Bolivia, Uruguay, and Argentina. AIDS Res Hum Retroviruses (2002) 1.50
Cancer surgeons' distress and well-being, II: modifiable factors and the potential for organizational interventions. Ann Surg Oncol (2011) 1.50
High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis (2005) 1.49
Clinical categorization for elective surgery in Victoria. ANZ J Surg (2003) 1.49
Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging (2003) 1.47
The natural history of HIV-1 infection in young Thai men after seroconversion. J Acquir Immune Defic Syndr (2004) 1.44
Cancer surgeons' distress and well-being, I: the tension between a culture of productivity and the need for self-care. Ann Surg Oncol (2011) 1.43
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One (2010) 1.41
Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents. J Infect Dis (2005) 1.41
Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine. Vaccine (2013) 1.40
Knowledge about vaccines and willingness to participate in preventive HIV vaccine trials: a population-based study, Rakai, Uganda. J Acquir Immune Defic Syndr (2004) 1.40
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr (2007) 1.39
A statewide system of trauma care in Victoria: effect on patient survival. Med J Aust (2008) 1.38
Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today (2004) 1.37
Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw (2008) 1.36
Outcomes in HIV-infected patients on antiretroviral therapy with tuberculosis. Southeast Asian J Trop Med Public Health (2007) 1.36
Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol (2004) 1.33
Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J Infect Dis (2003) 1.33
Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf (2007) 1.31
Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version 1.5. J Acquir Immune Defic Syndr (2002) 1.30
Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines (2004) 1.27
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol (2013) 1.26
Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PLoS One (2012) 1.25